Noven At a Glance

 (As of April 29, 2008)
Core Business: Specialty pharmaceutical company with expertise in transdermal drug delivery


Vivelle-Dot®,
the most prescribed transdermal estrogen therapy product in the U.S.
Year of IPO: 1988
Headquarters: Noven Pharmaceuticals, Inc
11960 SW 144th Street
Miami, Florida 33186
305-253-5099

Chairman
(Non-executive):

Wayne P. Yetter

President &
Chief Executive Officer:		 Peter C. Brandt
Vice President &
Chief Financial Officer:		 Michael D. Price
Investor, Media
and General Business Inquiries:		 Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
11960 SW 144th Street
Miami, Florida 33186
Ph: 305-253-1916
jjones@noven.com
Licensing and
Business Development
Inquiries:		 Pavan Handa
Vice President – Business Development
Ph: 305-964-3330
 phanda@noven.com
Affiliated Companies: Novogyne Pharmaceuticals –
a women’s health products company jointly owned by Noven and Novartis Pharmaceuticals Corporation

Noven Therapeutics, LLC
(f/k/a JDS Pharmaceuticals, LLC) –
a specialty pharmaceutical company acquired by Noven in August 2007
Employees: Approximately 580
NASDAQ Symbol: NOVN (Common Stock)
Shares Outstanding: Approximately 25 million
Fiscal Year End: December 31  
Key Products:

Pexeva®
(paroxetine mesylate)
Selective Serotonin Reuptake Inhibitor (SSRI)
Marketed by Noven Therapeutics, LLC

Lithobid®
(lithium carbonate)
Extended Release Lithium (U.S.)
Marketed by Noven Therapeutics, LLC

Daytrana™
(methylphenidate transdermal system)
Once-daily Transdermal Methylphenidate Patch (U.S.)
Marketed by Shire plc

Vivelle-Dot®
(estradiol transdermal system)
World’s Smallest Transdermal Estrogen Patch (U.S. & Canada)
Marketed by Novogyne Pharmaceuticals

CombiPatch®
(estradiol/norethindrone acetate)
Combination Estrogen/Progestogen Patch (U.S.)
Marketed by Novogyne Pharmaceuticals

Estradot®
(estradiol transdermal system)
World's Smallest Transdermal Estrogen Patch (Europe & elsewhere)
Marketed by Novartis

Estalis®
(estradiol/norethindrone acetate)
Combination Estrogen/Progestogen Patch (Europe & elsewhere)
Marketed by Novartis

Menorest®
(estradiol transdermal system)
Advanced Transdermal Estrogen Patch (Europe & elsewhere)
Marketed by Novartis
Research & Development: Oral products in development for psychiatric disorders, a non-hormonal oral product for menopausal symptoms, and a range of transdermal drug delivery systems for central nervous system disorders and other therapeutic areas.
Transfer Agent
& Registrar:		 American Stock Transfer and Trust Company
59 Maiden Lane
New York, New York 10038
Independent Auditors: Deloitte & Touche LLP
200 South Biscayne Boulevard
Suite 400
Miami, Florida 33131-2310
Patient, Physician
and Pharmacist Inquiries
Regarding Pexeva®
and Lithobid®:

Kendle International, Inc.
441 Vine Street
Suite 1200
Cincinnati, Ohio 45202
Attn: Safety Department
Ph: 800-455-8070

Patient, Physician
and Pharmacist Inquiries
Regarding Vivelle®,
Vivelle-Dot® or
CombiPatch®:

Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
Building 122
East Hanover, New Jersey 07936
Ph: 888-669-6682
Fax: 973-781-3115
Click here for E-mail Contact
Patient, Physician
and Pharmacist Inquiries
Regarding Daytrana™:

Shire US Inc.
725 Chesterbrook Blvd.
Wayne, PA 19087
Ph: 800-828-2088

Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.